Affiliation:
1. Department of Biomedical Engineering, University of Arkansas, Fayetteville, AR 72701, USA
2. Cell and Molecular Biology, University of Arkansas, Fayetteville, AR 72701, USA
Abstract
The CRISPR-Cas9 system is a revolutionary tool in genetic engineering, offering unprecedented precision and efficiency in genome editing. Cas9, an enzyme derived from bacteria, is guided by RNA to edit DNA sequences within cells precisely. However, while CRISPR-Cas9 presents notable benefits and encouraging outcomes as a molecular tool and a potential therapeutic agent, the process of producing and purifying recombinant Cas9 protein remains a formidable hurdle. In this study, we systematically investigated the expression of recombinant SpCas9-His in four distinct Escherichia coli (E. coli) strains (Rosetta2, BL21(DE3), BL21(DE3)-pLysS, and BL21(DE3)-Star). Through optimization of culture conditions, including temperature and post-induction time, the BL21(DE3)-pLysS strain demonstrated efficient SpCas9 protein expression. This study also presents a detailed protocol for the purification of recombinant SpCas9, along with detailed troubleshooting tips. Results indicate successful SpCas9 protein expression using E. coli BL21(DE3)-pLysS at 0.5 mM IPTG concentration. Furthermore, the findings suggest potential avenues for further enhancements, paving the way for large-scale Cas9 production. This research contributes valuable insights into optimizing E. coli strains and culture conditions for enhanced Cas9 expression, offering a step forward in the development of efficient genome editing tools and therapeutic proteins.
Funder
NIH/NIBIB
ASGCT Career Development Award
University of Arkansas Chancellor’s Innovation Grant
Arkansas Bioscience Institute
Women’s Giving Circle Grant
21st Century Chair in Biomedical Engineering
PhRMA Foundation 2023 Predoctoral Fellowship in Drug Discovery
Distinguished Doctoral Fellowship
NSF EPSCORE
Distinguished Doctoral Academy Fellowship
Fulbright Fellowship